がんバイオマーカー市場：生体分子タイプ別、がんタイプ別、技術別、用途別、エンドユーザー別-2023-2030年の世界予測

がんバイオマーカーの世界市場は、2023年にCAGR 12.13%で212億6,000万米ドル、2030年には474億6,000万米ドルに達すると予測され、大きく成長すると予測されています。

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは世界のがんバイオマーカー市場を評価するために不可欠です。事業戦略と製品満足度の主要指標を調査することで、ベンダーの包括的な評価を提供し、ユーザーは特定のニーズに基づいた情報をもとに意思決定を行うことができます。この高度な分析により、ベンダーは成功の度合いが異なる4つの象限に整理されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析では、特定の市場領域におけるベンダーの現状を洞察することができます。全体的な収益、顧客基盤、その他の主要指標に対するベンダーの貢献度を比較することで、企業が市場シェアを争う際に、自社の業績や直面している状況をより深く理解することができます。また、本分析では、調査した基準年において、特定のセクターがどの程度競合しているのか、蓄積、断片化の優位性、合併の特徴についても明らかにしています。

本レポートは、以下のポイントに関する洞察を提供します：

1.市場の浸透度：主要企業が提供する市場に関する包括的な情報を提供します。

2.市場の発展：有利な新興市場に関する詳細情報を提供し、市場の成熟セグメントにおける浸透度を分析します。

3.市場の多様化：新製品の上市、未開発地域、最近の開発、投資に関する詳細情報を提供します。

4.市場の動向：COVID-19、ロシア・ウクライナ紛争、高インフレの累積的な影響を包括的に理解することができます。

5.競合の評価と情報：主要企業の市場シェア、戦略、製品、認証、規制状況、特許状況、製造能力を網羅的に評価します。

6.製品開発およびイノベーション：将来技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような質問にお答えします：

1.がんバイオマーカーの世界市場規模および予測は？

2.予測期間中、世界のがんバイオマーカー市場を形成するCOVID-19の阻害要因と影響は？

3.がんバイオマーカーの世界市場において予測期間中に投資すべき製品/セグメント/アプリケーション/分野は？

4.がんバイオマーカーの世界市場における競争戦略は？

5.がんバイオマーカーの世界市場における技術動向と規制の枠組みは？

6.がんバイオマーカーの世界市場における主要ベンダーの市場シェアは？

7.がんバイオマーカーの世界市場への参入には、どのような形態や戦略的な動きが適していると考えられるか？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 世界的にがんの有病率が増加し、新興経済諸国での治療に対する受け入れ度が高まっている
    • 病気の診断からリスク評価または早期診断へのヘルスケアのパラダイムシフト
    • がんバイオマーカーの調査とテクノロジーの進歩
  • 抑制要因
    • 設備投資額が高く、給付率が低い
  • 機会
    • 個別化医療への需要の高まり
    • 対応する医薬品または生物学的製剤を安全かつ効果的に使用するためのコンパニオン診断の動向
  • 課題
    • 不利な償還ポリシーと規制の枠組み
• 市場動向
• COVID-19の累積的な影響
• ロシア・ウクライナ紛争の累積的影響
• 高インフレの累積的影響
• ポーターのファイブフォース分析
• バリューチェーンとクリティカルパス分析
• 規制の枠組み
• 顧客のカスタマイズ

第6章 がんバイオマーカー市場生体分子の種類別

• エピジェネティック
• 遺伝的
• 代謝
• プロテオミクス

第7章 がんバイオマーカー市場がんの種類別

• 血液がん
• 乳がん
• 結腸直腸がん
• 肺がん
• 卵巣がん
• 前立腺がん
• 皮膚ガン
• 胃がん

第8章 がんバイオマーカー市場：技術別

• バイオインフォマティクス
• 細胞遺伝学
• イメージング技術
• 免疫学的検査
• オミックステクノロジー

第9章 がんバイオマーカー市場：用途別

• 診断
• 創薬と開発
• 予後
• リスクアセスメント

第10章 がんバイオマーカー市場：エンドユーザー別

• 学術およびがん研究センター
• 病院
• 専門センター

第11章 南北アメリカのがんバイオマーカー市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第12章 アジア太平洋地域のがんバイオマーカー市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第13章 欧州・中東・アフリカのがんバイオマーカー市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第14章 競合情勢

• FPNVポジショニングマトリクス
• 市場シェア分析：主要企業別
• 競合シナリオ分析：主要企業別

第15章 掲載企業一覧

第16章 付録

• ディスカッションガイド
• ライセンスと価格について

LIST OF FIGURES

• FIGURE 1. CANCER BIOMARKERS MARKET RESEARCH PROCESS
• FIGURE 2. CANCER BIOMARKERS MARKET SIZE, 2022 VS 2030
• FIGURE 3. CANCER BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. CANCER BIOMARKERS MARKET SIZE, BY BIOMOLECULE TYPE, 2022 VS 2030 (%)
• FIGURE 5. CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2022 VS 2030 (%)
• FIGURE 6. CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2022 VS 2030 (%)
• FIGURE 7. CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2022 VS 2030 (%)
• FIGURE 8. CANCER BIOMARKERS MARKET SIZE, BY END USER, 2022 VS 2030 (%)
• FIGURE 9. CANCER BIOMARKERS MARKET SIZE, BY REGION, 2022 VS 2030 (%)
• FIGURE 10. CANCER BIOMARKERS MARKET DYNAMICS
• FIGURE 11. CANCER BIOMARKERS MARKET SIZE, BY BIOMOLECULE TYPE, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 12. CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 13. CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 14. CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 15. CANCER BIOMARKERS MARKET SIZE, BY END USER, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 16. AMERICAS CANCER BIOMARKERS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 17. UNITED STATES CANCER BIOMARKERS MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 18. ASIA-PACIFIC CANCER BIOMARKERS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA CANCER BIOMARKERS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 20. CANCER BIOMARKERS MARKET, FPNV POSITIONING MATRIX, 2022
• FIGURE 21. CANCER BIOMARKERS MARKET SHARE, BY KEY PLAYER, 2022

LIST OF TABLES

• TABLE 1. CANCER BIOMARKERS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
• TABLE 3. CANCER BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. CANCER BIOMARKERS MARKET SIZE, BY BIOMOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 5. CANCER BIOMARKERS MARKET SIZE, BY EPIGENETIC, BY REGION, 2018-2030 (USD MILLION)
• TABLE 6. CANCER BIOMARKERS MARKET SIZE, BY GENETIC, BY REGION, 2018-2030 (USD MILLION)
• TABLE 7. CANCER BIOMARKERS MARKET SIZE, BY METABOLIC, BY REGION, 2018-2030 (USD MILLION)
• TABLE 8. CANCER BIOMARKERS MARKET SIZE, BY PROTEOMIC, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 10. CANCER BIOMARKERS MARKET SIZE, BY BLOOD CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. CANCER BIOMARKERS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. CANCER BIOMARKERS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. CANCER BIOMARKERS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. CANCER BIOMARKERS MARKET SIZE, BY OVARIAN CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. CANCER BIOMARKERS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. CANCER BIOMARKERS MARKET SIZE, BY SKIN CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. CANCER BIOMARKERS MARKET SIZE, BY STOMACH CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 19. CANCER BIOMARKERS MARKET SIZE, BY BIOINFORMATICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. CANCER BIOMARKERS MARKET SIZE, BY CYTOGENETICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. CANCER BIOMARKERS MARKET SIZE, BY IMAGING TECHNOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. CANCER BIOMARKERS MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. CANCER BIOMARKERS MARKET SIZE, BY OMICS TECHNOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 25. CANCER BIOMARKERS MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. CANCER BIOMARKERS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. CANCER BIOMARKERS MARKET SIZE, BY PROGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. CANCER BIOMARKERS MARKET SIZE, BY RISK ASSESSMENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 30. CANCER BIOMARKERS MARKET SIZE, BY ACADEMIC & CANCER RESEARCH CENTERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 31. CANCER BIOMARKERS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 32. CANCER BIOMARKERS MARKET SIZE, BY SPECIALITY CENTERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 33. AMERICAS CANCER BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 34. AMERICAS CANCER BIOMARKERS MARKET SIZE, BY BIOMOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 35. AMERICAS CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 36. AMERICAS CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 37. AMERICAS CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 38. AMERICAS CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 39. ARGENTINA CANCER BIOMARKERS MARKET SIZE, BY BIOMOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 40. ARGENTINA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 41. ARGENTINA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 42. ARGENTINA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 43. ARGENTINA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 44. BRAZIL CANCER BIOMARKERS MARKET SIZE, BY BIOMOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 45. BRAZIL CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 46. BRAZIL CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 47. BRAZIL CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 48. BRAZIL CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 49. CANADA CANCER BIOMARKERS MARKET SIZE, BY BIOMOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 50. CANADA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 51. CANADA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 52. CANADA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 53. CANADA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 54. MEXICO CANCER BIOMARKERS MARKET SIZE, BY BIOMOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 55. MEXICO CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 56. MEXICO CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 57. MEXICO CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 58. MEXICO CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 59. UNITED STATES CANCER BIOMARKERS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 60. UNITED STATES CANCER BIOMARKERS MARKET SIZE, BY BIOMOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 61. UNITED STATES CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 62. UNITED STATES CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 63. UNITED STATES CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 64. UNITED STATES CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 65. ASIA-PACIFIC CANCER BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 66. ASIA-PACIFIC CANCER BIOMARKERS MARKET SIZE, BY BIOMOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 67. ASIA-PACIFIC CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 68. ASIA-PACIFIC CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 69. ASIA-PACIFIC CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 70. ASIA-PACIFIC CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 71. AUSTRALIA CANCER BIOMARKERS MARKET SIZE, BY BIOMOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 72. AUSTRALIA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 73. AUSTRALIA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 74. AUSTRALIA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 75. AUSTRALIA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 76. CHINA CANCER BIOMARKERS MARKET SIZE, BY BIOMOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 77. CHINA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 78. CHINA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 79. CHINA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 80. CHINA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 81. INDIA CANCER BIOMARKERS MARKET SIZE, BY BIOMOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 82. INDIA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 83. INDIA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 84. INDIA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 85. INDIA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 86. INDONESIA CANCER BIOMARKERS MARKET SIZE, BY BIOMOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 87. INDONESIA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 88. INDONESIA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 89. INDONESIA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 90. INDONESIA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 91. JAPAN CANCER BIOMARKERS MARKET SIZE, BY BIOMOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 92. JAPAN CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 93. JAPAN CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 94. JAPAN CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 95. JAPAN CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 96. MALAYSIA CANCER BIOMARKERS MARKET SIZE, BY BIOMOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 97. MALAYSIA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 98. MALAYSIA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 99. MALAYSIA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 100. MALAYSIA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 101. PHILIPPINES CANCER BIOMARKERS MARKET SIZE, BY BIOMOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 102. PHILIPPINES CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 103. PHILIPPINES CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 104. PHILIPPINES CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 105. PHILIPPINES CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 106. SINGAPORE CANCER BIOMARKERS MARKET SIZE, BY BIOMOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 107. SINGAPORE CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 108. SINGAPORE CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 109. SINGAPORE CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 110. SINGAPORE CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 111. SOUTH KOREA CANCER BIOMARKERS MARKET SIZE, BY BIOMOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 112. SOUTH KOREA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 113. SOUTH KOREA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 114. SOUTH KOREA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 115. SOUTH KOREA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 116. TAIWAN CANCER BIOMARKERS MARKET SIZE, BY BIOMOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 117. TAIWAN CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 118. TAIWAN CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 119. TAIWAN CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 120. TAIWAN CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 121. THAILAND CANCER BIOMARKERS MARKET SIZE, BY BIOMOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 122. THAILAND CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 123. THAILAND CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 124. THAILAND CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 125. THAILAND CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 126. VIETNAM CANCER BIOMARKERS MARKET SIZE, BY BIOMOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 127. VIETNAM CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 128. VIETNAM CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 129. VIETNAM CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 130. VIETNAM CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 131. EUROPE, MIDDLE EAST & AFRICA CANCER BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 132. EUROPE, MIDDLE EAST & AFRICA CANCER BIOMARKERS MARKET SIZE, BY BIOMOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 133. EUROPE, MIDDLE EAST & AFRICA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 134. EUROPE, MIDDLE EAST & AFRICA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 135. EUROPE, MIDDLE EAST & AFRICA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 136. EUROPE, MIDDLE EAST & AFRICA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 137. DENMARK CANCER BIOMARKERS MARKET SIZE, BY BIOMOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 138. DENMARK CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 139. DENMARK CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 140. DENMARK CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 141. DENMARK CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 142. EGYPT CANCER BIOMARKERS MARKET SIZE, BY BIOMOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 143. EGYPT CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 144. EGYPT CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 145. EGYPT CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 146. EGYPT CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 147. FINLAND CANCER BIOMARKERS MARKET SIZE, BY BIOMOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 148. FINLAND CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 149. FINLAND CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 150. FINLAND CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 151. FINLAND CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 152. FRANCE CANCER BIOMARKERS MARKET SIZE, BY BIOMOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 153. FRANCE CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 154. FRANCE CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 155. FRANCE CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 156. FRANCE CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 157. GERMANY CANCER BIOMARKERS MARKET SIZE, BY BIOMOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 158. GERMANY CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 159. GERMANY CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 160. GERMANY CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 161. GERMANY CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 162. ISRAEL CANCER BIOMARKERS MARKET SIZE, BY BIOMOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 163. ISRAEL CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 164. ISRAEL CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 165. ISRAEL CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 166. ISRAEL CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 167. ITALY CANCER BIOMARKERS MARKET SIZE, BY BIOMOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 168. ITALY CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 169. ITALY CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 170. ITALY CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 171. ITALY CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 172. NETHERLANDS CANCER BIOMARKERS MARKET SIZE, BY BIOMOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 173. NETHERLANDS CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 174. NETHERLANDS CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 175. NETHERLANDS CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 176. NETHERLANDS CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 177. NIGERIA CANCER BIOMARKERS MARKET SIZE, BY BIOMOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 178. NIGERIA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 179. NIGERIA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 180. NIGERIA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 181. NIGERIA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 182. NORWAY CANCER BIOMARKERS MARKET SIZE, BY BIOMOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 183. NORWAY CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 184. NORWAY CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 185. NORWAY CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 186. NORWAY CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 187. POLAND CANCER BIOMARKERS MARKET SIZE, BY BIOMOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 188. POLAND CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 189. POLAND CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 190. POLAND CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 191. POLAND CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 192. QATAR CANCER BIOMARKERS MARKET SIZE, BY BIOMOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 193. QATAR CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 194. QATAR CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 195. QATAR CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 196. QATAR CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 197. RUSSIA CANCER BIOMARKERS MARKET SIZE, BY BIOMOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 198. RUSSIA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 199. RUSSIA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 200. RUSSIA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 201. RUSSIA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 202. SAUDI ARABIA CANCER BIOMARKERS MARKET SIZE, BY BIOMOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 203. SAUDI ARABIA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 204. SAUDI ARABIA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 205. SAUDI ARABIA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 206. SAUDI ARABIA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 207. SOUTH AFRICA CANCER BIOMARKERS MARKET SIZE, BY BIOMOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 208. SOUTH AFRICA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 209. SOUTH AFRICA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 210. SOUTH AFRICA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 211. SOUTH AFRICA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 212. SPAIN CANCER BIOMARKERS MARKET SIZE, BY BIOMOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 213. SPAIN CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 214. SPAIN CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 215. SPAIN CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 216. SPAIN CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 217. SWEDEN CANCER BIOMARKERS MARKET SIZE, BY BIOMOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 218. SWEDEN CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 219. SWEDEN CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 220. SWEDEN CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 221. SWEDEN CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 222. SWITZERLAND CANCER BIOMARKERS MARKET SIZE, BY BIOMOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 223. SWITZERLAND CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 224. SWITZERLAND CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 225. SWITZERLAND CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 226. SWITZERLAND CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 227. TURKEY CANCER BIOMARKERS MARKET SIZE, BY BIOMOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 228. TURKEY CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 229. TURKEY CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 230. TURKEY CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 231. TURKEY CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 232. UNITED ARAB EMIRATES CANCER BIOMARKERS MARKET SIZE, BY BIOMOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 233. UNITED ARAB EMIRATES CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 234. UNITED ARAB EMIRATES CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 235. UNITED ARAB EMIRATES CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 236. UNITED ARAB EMIRATES CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 237. UNITED KINGDOM CANCER BIOMARKERS MARKET SIZE, BY BIOMOLECULE TYPE, 2018-2030 (USD MILLION)
• TABLE 238. UNITED KINGDOM CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 239. UNITED KINGDOM CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 240. UNITED KINGDOM CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 241. UNITED KINGDOM CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 242. CANCER BIOMARKERS MARKET, FPNV POSITIONING MATRIX, 2022
• TABLE 243. CANCER BIOMARKERS MARKET SHARE, BY KEY PLAYER, 2022
• TABLE 244. CANCER BIOMARKERS MARKET LICENSE & PRICING

The Global Cancer Biomarkers Market is forecasted to grow significantly, with a projected USD 21.26 billion in 2023 at a CAGR of 12.13% and expected to reach a staggering USD 47.46 billion by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Cancer Biomarkers Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Cancer Biomarkers Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Biomolecule Type, market is studied across Epigenetic, Genetic, Metabolic, and Proteomic. The Epigenetic is projected to witness significant market share during forecast period.

Based on Cancer Type, market is studied across Blood Cancer, Breast Cancer, Colorectal Cancer, Lung Cancer, Ovarian Cancer, Prostate Cancer, Skin Cancer, and Stomach Cancer. The Ovarian Cancer is projected to witness significant market share during forecast period.

Based on Technology, market is studied across Bioinformatics, Cytogenetics, Imaging Technology, Immunoassays, and OMICS Technology. The Bioinformatics is projected to witness significant market share during forecast period.

Based on Application, market is studied across Diagnostics, Drug Discovery & Development, Prognostics, and Risk Assessment. The Drug Discovery & Development is projected to witness significant market share during forecast period.

Based on End User, market is studied across Academic & Cancer Research Centers, Hospitals, and Speciality Centers. The Hospitals is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 38.75% in 2022, followed by Europe, Middle East & Africa.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Cancer Biomarkers Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Cancer Biomarkers Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Cancer Biomarkers Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Cancer Biomarkers Market?

4. What is the competitive strategic window for opportunities in the Global Cancer Biomarkers Market?

5. What are the technology trends and regulatory frameworks in the Global Cancer Biomarkers Market?

6. What is the market share of the leading vendors in the Global Cancer Biomarkers Market?

7. What modes and strategic moves are considered suitable for entering the Global Cancer Biomarkers Market?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Limitations
• 1.7. Assumptions
• 1.8. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

• 4.1. Introduction
• 4.2. Cancer Biomarkers Market, by Biomolecule Type, 2022 vs 2030
• 4.3. Cancer Biomarkers Market, by Cancer Type, 2022 vs 2030
• 4.4. Cancer Biomarkers Market, by Technology, 2022 vs 2030
• 4.5. Cancer Biomarkers Market, by Application, 2022 vs 2030
• 4.6. Cancer Biomarkers Market, by End User, 2022 vs 2030
• 4.7. Cancer Biomarkers Market, by Region, 2022 vs 2030

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing prevalence of cancer globally and higher acceptance for treatment in developing economies
    • 5.1.1.2. Paradigm shift in healthcare from disease diagnosis to risk assessment or early diagnosis
    • 5.1.1.3. Technology advancement coupled with the research on cancer biomarkers
  • 5.1.2. Restraints
    • 5.1.2.1. High capital investment associated with low benefit ratio
  • 5.1.3. Opportunities
    • 5.1.3.1. Growing demand for personalized medicines
    • 5.1.3.2. Trend of the companion diagnostic for the safe and effective use of a corresponding drug or biological product
  • 5.1.4. Challenges
    • 5.1.4.1. Unfavorable reimbursement policies and regulatory framework
• 5.2. Market Trends
• 5.3. Cumulative Impact of COVID-19
• 5.4. Cumulative Impact of Russia-Ukraine Conflict
• 5.5. Cumulative Impact of High Inflation
• 5.6. Porter's Five Forces Analysis
  • 5.6.1. Threat of New Entrants
  • 5.6.2. Threat of Substitutes
  • 5.6.3. Bargaining Power of Customers
  • 5.6.4. Bargaining Power of Suppliers
  • 5.6.5. Industry Rivalry
• 5.7. Value Chain & Critical Path Analysis
• 5.8. Regulatory Framework
• 5.9. Client Customization

6. Cancer Biomarkers Market, by Biomolecule Type

• 6.1. Introduction
• 6.2. Epigenetic
• 6.3. Genetic
• 6.4. Metabolic
• 6.5. Proteomic

7. Cancer Biomarkers Market, by Cancer Type

• 7.1. Introduction
• 7.2. Blood Cancer
• 7.3. Breast Cancer
• 7.4. Colorectal Cancer
• 7.5. Lung Cancer
• 7.6. Ovarian Cancer
• 7.7. Prostate Cancer
• 7.8. Skin Cancer
• 7.9. Stomach Cancer

8. Cancer Biomarkers Market, by Technology

• 8.1. Introduction
• 8.2. Bioinformatics
• 8.3. Cytogenetics
• 8.4. Imaging Technology
• 8.5. Immunoassays
• 8.6. OMICS Technology

9. Cancer Biomarkers Market, by Application

• 9.1. Introduction
• 9.2. Diagnostics
• 9.3. Drug Discovery & Development
• 9.4. Prognostics
• 9.5. Risk Assessment

10. Cancer Biomarkers Market, by End User

• 10.1. Introduction
• 10.2. Academic & Cancer Research Centers
• 10.3. Hospitals
• 10.4. Speciality Centers

11. Americas Cancer Biomarkers Market

• 11.1. Introduction
• 11.2. Argentina
• 11.3. Brazil
• 11.4. Canada
• 11.5. Mexico
• 11.6. United States

12. Asia-Pacific Cancer Biomarkers Market

• 12.1. Introduction
• 12.2. Australia
• 12.3. China
• 12.4. India
• 12.5. Indonesia
• 12.6. Japan
• 12.7. Malaysia
• 12.8. Philippines
• 12.9. Singapore
• 12.10. South Korea
• 12.11. Taiwan
• 12.12. Thailand
• 12.13. Vietnam

13. Europe, Middle East & Africa Cancer Biomarkers Market

• 13.1. Introduction
• 13.2. Denmark
• 13.3. Egypt
• 13.4. Finland
• 13.5. France
• 13.6. Germany
• 13.7. Israel
• 13.8. Italy
• 13.9. Netherlands
• 13.10. Nigeria
• 13.11. Norway
• 13.12. Poland
• 13.13. Qatar
• 13.14. Russia
• 13.15. Saudi Arabia
• 13.16. South Africa
• 13.17. Spain
• 13.18. Sweden
• 13.19. Switzerland
• 13.20. Turkey
• 13.21. United Arab Emirates
• 13.22. United Kingdom

14. Competitive Landscape

• 14.1. FPNV Positioning Matrix
• 14.2. Market Share Analysis, By Key Player
• 14.3. Competitive Scenario Analysis, By Key Player

15. List of Company Mentioned

16. Appendix

• 16.1. Discussion Guide
• 16.2. License & Pricing